UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT ~~PURSUANT~~Pursuant to Section 13 or 15(d) of the

TOSecurities ~~SECTION 13~~Exchange ORAct ~~15(D)~~of ~~OF THE~~1934

~~SECURITIES EXCHANGE~~Date ~~ACT~~of OFReport ~~1934~~(Date of earliest event reported): November 15, 2021

~~Date~~American CryoStem Corporation (Exact name of ~~Report: April~~registrant ~~27,~~as ~~2018~~specified in its chapter)

Commission File Number 000-54672


Nevada	000-54672	26-4574088

(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

_____________________________________________________________

1 Meridian Road, Eatontown, NJ

07724

(Address of principal executive offices)

(Zip Code)

~~American~~Registrant’s ~~CryoStem Corporation~~telephone number, including area code: (732) 747-1007

(~~Exact~~Former name ~~of Registrant~~or asformer ~~specified~~address, inif ~~its~~changed ~~charter~~since last report)

~~____________________________________________________________________________~~Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Nevada	7812	26-4574088
(State or other jurisdiction of incorporation or organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification Code Number)


x	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1Securities ~~Meridian~~registered ~~Road,~~pursuant ~~Suite~~to 5Section ~~Eatontown, NJ 07724~~ 12(~~Address~~b) of ~~principal~~the ~~executive offices) (732) 747-1007 (Registrant’s telephone number, including area code)~~Act:

~~Check~~Title ~~the~~of ~~appropriate~~each ~~box~~class ~~below~~Trading ~~if the~~symbol(s) ~~Form~~Name ~~8-K filing is intended to simultaneously satisfy the filing obligation~~ of ~~the~~each ~~Registrant~~exchange ~~under~~on ~~any~~which ~~of the following provisions (see General Instruction A.2. below):~~registered

oIndicate ~~Written~~by ~~communications~~check ~~pursuant~~mark towhether the registrant is an emerging growth company as defined in Rule ~~425~~405 ~~under~~of the Securities Act ~~(17~~of ~~CFR~~1933 (§230.~~425~~405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

~~o Soliciting material~~ Emerging ~~pursuant~~growth tocompany ~~Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)~~o

oIf ~~Pre-commencement~~an ~~communications~~emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to ~~Rule~~Section ~~14d-2~~13(ba) ~~under~~of the Exchange Act ~~(17CFR 240~~.~~14d-2(b))~~ o

oItem ~~Pre-commencement~~5.03. ~~communications~~Amendments ~~pursuant~~ to ~~Rule 13-e-4(c)~~Articles ~~under~~of ~~the~~Incorporation ~~Exchange~~or ~~Act~~Bylaws; ~~(17~~Change ~~CFR~~in ~~240~~Fiscal Year.~~13e-4(c))~~

~~FOWARD~~Pursuant ~~LOOKING STATEMENTS~~to ~~UNDER~~a ~~THE~~Share ~~PROVATE~~Exchange ~~SECURITIES~~Agreement, ~~LITIGATION~~dated ~~REFORM~~as ~~ACT~~of OFNovember ~~1995~~12, 2021, by and between American CryoStem Corporation, a Nevada corporation (the “Company”) and ASC Global, Inc., a Nevada corporation, whose shares of common stock are quoted on the OTC Market Group’s OTC Pink Tier Market under the symbol “AMCY” (“AMCY”), the Company issued to AMCY 1,000,000 shares of its Series A convertible preferred stock (the “A Shares”) in exchange for 20,000,000 shares of common stock, par value $0.001 per share, of the Company held by AMCY, reducing the outstanding shares of the Company’s common stock from 62,057,355 to 42,057,355. Each A Share will be convertible at the option of AMCY into twenty (20) shares of the Company’s common stock commencing on November 11, 2022 and, subject to Nevada law, is entitled to an annual dividend equal to $0.20 per A Share payable quarterly, in cash, or at the option of the Company, in shares of Company common stock with each such share of common stock having a value for such purposes equal to the average VWAP for the five (5) consecutive trading days with the fifth consecutive trading day being the last trading day of the calendar quarter for which such dividend is being paid.

~~This~~Except ~~Current Report~~as ~~and~~required ~~other reports filed~~ by ~~American~~Nevada ~~CryoStem~~law ~~Corporation ("CRYO"~~ or ~~the~~otherwise ~~"Registrant")~~provided ~~from~~in ~~time to time with~~ the U.S. Securities and Exchange Commission (the “SEC”) contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the RegistrantCompany’s ~~management~~Certificate asof ~~well as~~Designation ~~estimates~~of ~~and assumptions made by Registrant’s management. Readers are cautioned not to place undue reliance on these forward-looking statements~~Rights, ~~which~~Preferences ~~are only predictions~~ and ~~speak~~Privileges ~~only as~~ of ~~the~~Series ~~date~~A ~~hereof. When~~Convertible ~~used~~Preferred ~~in the~~Stock ~~filings,~~ (the ~~words~~ “~~anticipate,”~~Certificate ~~“believe,”~~of ~~“estimate,~~Designation” ~~“expect~~),” ~~“future,” “intend,” “plan,” or~~ the ~~negative~~A ofShares ~~these~~shall ~~terms~~vote ~~and similar expressions~~ as ~~they~~common ~~relate~~stock toon ~~the~~an ~~Registrant or the Registrant’s management identify forward~~as-~~looking~~converted ~~statements. Such~~basis ~~statements reflect the current view of the Registrant~~ with ~~respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including~~ the ~~risks contained in the “Risk Factors” section of the this Annual Report on Form 10-K., relating to the Registrant~~Company’s ~~industry,~~ ~~the~~then ~~Registrant’s~~outstanding ~~operations~~common ~~and results of operations, and any businesses that the Registrant may acquire~~stock. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

~~ITEM~~The ~~7.01.~~above ~~Regulation~~is FDa ~~Disclosure~~summary only of the rights, preferences and privileges of the A Shares and is qualified in its entirety to the Certificate of Designation attached hereto as Exhibit 3.1.

~~Correction~~John Arnone and Anthony Dudzinski, the sole officers and directors of ~~Press~~the ~~Release~~Company ~~dated~~who ~~April~~collectively 5beneficially own 30,260,000 ~~2018~~shares of common stock of the Company, or approximately 45.4% of the outstanding Company common stock are the sole officers and directors of AMCY and collectively beneficially own 48,270,000 shares of common stock of AMCY, or 59.5% of the outstanding AMCY common stock.

~~The~~Item ~~Company today is providing a correction to the description of Cryoviva Ltd~~9.01. ~~contained~~Financial inStatements ~~its~~and ~~press release dated April 5, 2018 titled:~~Exhibits.

~~“American~~(d) ~~CryoStem Enters Into Agreement to License its Patented Adipose Tissue and Stem Cell Technologies in Thailand”~~Exhibits:

The “About Cryoviva” section is updated and corrected to:

Exhibit No.		Description
3.1		Certificate of Designation of Rights, Preferences and Privileges of Series A Convertible Preferred Stock.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

About Cryoviva

Cryoviva (Thailand) Ltd. was established in 2007 with the cooperation of leading companies in the world such as Indorama Ventures (Public) Company Limited, Thailand, Cryoviva Biotech Pvt., Ltd., (formerly known as Cryobanks International India) and RJ Corp India. Cryoviva is part of a large group engaged in healthcare comprising of stem cell banks, stem cell expansion facilities, diagnostic labs and centres and a maternal hospital. The Company has been certified by AABB and the ISO 9001: 2008 Quality Management System. Cryoviva (Thailand) Co., Ltd. is the only stem cell bank that has been approved by the Board of Investment of Thailand (BOI) and accredited by AABB in Thailand and awarded Frost & Sullivan’s Thailand Stem Cell Company of the year for three consecutive years between 2015-2017.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. Exhibit 99.1 Corrected press release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned ~~hereunto~~, thereunto duly authorized.

AMERICAN CRYOSTEM CORPORATION By: /s/ John S. Arnone John S. Arnone President, CEO and Chairman of the Board

	AMERICAN CRYOSTEM CORPORATION

Date: November 15, 2021	By:	/s/ John S. Arnone
		John S. Arnone
		Chief Executive Officer, President and Chairman

Filing Compare · American CryoStem Corp